Compugen Ltd.
A clinical-stage company developing cancer immunotherapies using an AI platform.
CGEN | TA
Overview
Corporate Details
- ISIN(s):
- IL0010852080
- LEI:
- Country:
- Israel
- Address:
- 26 Harokmim St., Bldg D, 5885849 Holon
- Website:
- https://www.cgen.com/
Description
Compugen Ltd. is a clinical-stage therapeutic discovery and development company specializing in cancer immunotherapy. A pioneer in its field, the company leverages a proprietary, broadly applicable, and predictive AI-powered computational discovery platform to identify novel drug targets. Its primary focus is on developing innovative, first-in-class therapeutics designed to modulate the tumor microenvironment and enhance anti-tumor immune responses. Compugen's mission is to advance its pipeline of drug candidates to address patient populations unresponsive to current immunotherapy treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-05-15 15:59 |
Compugen Appoints David Silberman as Chief Financial Officer
|
English | 36.2 KB | ||
| 2024-05-06 15:59 |
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024, confere…
|
English | 88.7 KB | ||
| 2024-05-06 15:59 |
Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024, confere…
|
English | 36.3 KB | ||
| 2024-04-25 15:59 |
to Present New Clinical Data Showing COM701 Triple
Combination Preliminary Ant…
|
English | 92.4 KB | ||
| 2024-04-25 15:59 |
to Present New Clinical Data Showing COM701 Triple
Combination Preliminary Ant…
|
English | 36.2 KB | ||
| 2024-04-10 15:59 |
Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potenti…
|
English | 112.7 KB | ||
| 2024-04-10 15:59 |
Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potenti…
|
English | 36.3 KB | ||
| 2024-04-03 15:59 |
Compugen to Participate in Two Upcoming Investor Conferences
|
English | 96.1 KB | ||
| 2024-04-03 15:59 |
Compugen to Participate in Two Upcoming Investor Conferences
|
English | 36.3 KB | ||
| 2024-03-11 13:59 |
Selected for two Oral Presentations at the
Keystone Symposium on Cancer Immunot…
|
English | 88.3 KB | ||
| 2024-03-11 13:59 |
Selected for two Oral Presentations at the
Keystone Symposium on Cancer Immunot…
|
English | 36.2 KB | ||
| 2024-03-06 14:59 |
to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
|
English | 100.2 KB | ||
| 2024-03-06 14:59 |
to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
|
English | 36.2 KB | ||
| 2024-03-06 00:20 |
FORM 20-F For the fiscal year ended December 31, 2023
|
English | 1.8 MB | ||
| 2024-03-06 00:20 |
FORM 20-F For the fiscal year ended December 31, 2023
|
English | 36.4 KB |
Automate Your Workflow. Get a real-time feed of all Compugen Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Compugen Ltd.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Compugen Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
